In an ambitious bid to reshape drug discovery with cutting-edge artificial intelligence, Nvidia and pharmaceutical giant Eli Lilly announced a $1 billion collaboration to build a joint research lab in the San Francisco Bay Area. Over the next five years, this venture will harness Nvidia’s latest Vera Rubin AI computing platform, forging a new frontier where big pharma and AI collide.
![Indianapolis - Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals [Getty Images]](https://www.founded.com/wp-content/uploads/2026/01/GettyImages-1793099940-1-1-1024x576.jpg)
Founded in 1993 by Jensen Huang, Chris Malachowsky, and Curtis Priem, Nvidia transformed from a graphics chip startup into a powerhouse for AI compute. Eli Lilly, meanwhile, traces its roots back to 1876 when its founder, Colonel Eli Lilly, combined pharmaceutical knowledge with a commitment to innovation, growing the company into a global leader in life sciences.
The billion-dollar question fuelling the future of AI and medicine
The lab will bring together researchers from both companies to develop AI-driven methods for designing and discovering new medicines – an evolution from previous projects. Last year, Eli Lilly unveiled plans for a supercomputer built on more than 1,000 Nvidia Grace Blackwell GPUs to accelerate drug development.
At the center of the collaboration is Nvidia’s Vera Rubin NVL72 platform, a large AI system built to handle the heavy computing needed for life sciences research, along with open-source tools like BioNeMo that help speed up biotech research.
Both firms see AI as a solution to the painful bottlenecks in drug R&D, with the potential to slash time to market for new treatments. The development cycle has long been slow and expensive, which is a huge problem when lives often depend on speed and precision.
If the lab succeeds in producing validated AI models and datasets, it could help reduce the time and cost required to reach early proof-of-concept stages for new drugs.
